NPI: 1801020193 · MISSION, TX 78572 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 05/14/2009
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 05/14/2009 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2021 | 4,332 | $2K |
| 2022 | 1,394 | $10K |
| 2024 | 120 | $14K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 344 | 48 | $25K |
| 83970 | 361 | 331 | $181.07 | |
| 82728 | 261 | 252 | $39.73 | |
| 83550 | 396 | 367 | $22.69 | |
| 83540 | 396 | 367 | $18.86 | |
| 85041 | 401 | 376 | $8.45 | |
| 85048 | 374 | 349 | $5.22 | |
| 82108 | 31 | 30 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 315 | 296 | $0.00 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 95 | 54 | $0.00 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 2,872 | 173 | $0.00 |